Atossa Genetics (ATOS) Financials

Atossa Genetics logo
$1.60 -0.15 (-8.57%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$1.67 +0.07 (+4.44%)
As of 11/20/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Atossa Genetics

Annual Income Statements for Atossa Genetics

This table shows Atossa Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-16 -6.37 -11 -23 -17 -22 -21 -27 -30 -26 -35
Consolidated Net Income / (Loss)
-16 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Net Income / (Loss) Continuing Operations
-13 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Total Pre-Tax Income
-13 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Total Operating Income
-13 -7.97 -7.65 -11 -17 -15 -21 -28 -31 -28 -37
Total Gross Profit
-0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
13 7.97 7.65 11 17 15 21 28 31 28 37
Selling, General & Admin Expense
10 6.48 4.86 7.22 11 8.00 11 13 14 14 16
Research & Development Expense
2.36 0.77 2.33 4.21 6.65 6.61 9.21 15 17 14 21
Total Other Income / (Expense), net
0.00 1.60 -0.47 0.03 0.03 -3.22 -0.09 0.73 1.28 2.12 2.37
Interest & Investment Income
- - - - - - 0.01 0.88 4.34 2.34 2.38
Other Income / (Expense), net
0.00 1.60 -0.47 0.03 0.03 -3.22 -0.09 -0.15 -3.06 -0.22 -0.01
Income Tax Expense
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share
($8.31) ($2.16) ($10.97) ($5.50) ($2.03) ($1.97) ($0.18) ($0.21) ($0.24) ($3.04) ($4.04)
Weighted Average Basic Shares Outstanding
1.90M 2.95M 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 126.08M 8.39M 8.61M
Diluted Earnings per Share
($8.31) ($2.16) ($10.97) ($5.50) ($2.03) ($1.97) - ($0.21) ($0.24) ($3.04) ($4.04)
Weighted Average Diluted Shares Outstanding
1.90M 2.95M 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 126.08M 8.39M 8.61M
Weighted Average Basic & Diluted Shares Outstanding
1.90M 2.95M 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 125.30M 129.17M 8.61M

Quarterly Income Statements for Atossa Genetics

This table shows Atossa Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59 -8.49 -5.64
Consolidated Net Income / (Loss)
-5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59 -8.49 -5.64
Net Income / (Loss) Continuing Operations
-5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59 -8.49 -5.64
Total Pre-Tax Income
-5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59 -8.49 -5.64
Total Operating Income
-6.98 -7.11 -6.39 -7.15 -7.41 -9.04 -9.25 -11 -9.87 -8.69 -5.90
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
6.98 7.11 6.39 7.15 7.41 9.04 9.25 11 9.87 8.69 5.90
Selling, General & Admin Expense
3.23 3.55 2.97 3.75 3.26 3.54 3.88 5.28 5.09 3.80 2.52
Research & Development Expense
3.75 3.55 3.41 3.40 4.16 5.50 5.37 6.16 4.78 4.90 3.38
Total Other Income / (Expense), net
1.10 1.06 -0.85 0.80 0.70 0.62 0.56 0.50 0.28 0.20 0.26
Interest & Investment Income
1.14 1.07 -0.71 -0.87 0.72 0.65 0.57 0.44 0.31 0.23 0.21
Other Income / (Expense), net
-0.04 -0.02 -0.14 1.68 -0.02 -0.03 -0.01 0.06 -0.03 -0.02 0.05
Income Tax Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Basic Earnings per Share
($0.05) ($0.05) ($0.06) ($0.04) ($0.78) ($0.98) ($1.01) ($1.27) ($1.11) ($0.95) ($0.56)
Weighted Average Basic Shares Outstanding
125.32M 125.73M 125.77M 125.86M 8.62M 8.62M 8.62M 8.61M 8.62M 8.91M 9.99M
Diluted Earnings per Share
($0.05) ($0.05) ($0.06) ($0.04) ($0.78) ($0.98) ($1.01) ($1.27) ($1.11) ($0.95) ($0.56)
Weighted Average Diluted Shares Outstanding
125.32M 125.73M 125.77M 125.86M 8.62M 8.62M 8.62M 8.61M 8.62M 8.91M 9.99M

Annual Cash Flow Statements for Atossa Genetics

This table details how cash moves in and out of Atossa Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-4.78 -0.69 4.19 3.22 2.20 27 97 -25 -22 -17 -30
Net Cash From Operating Activities
-14 -5.37 -6.59 -8.96 -9.13 -12 -16 -21 -21 -21 -30
Net Cash From Continuing Operating Activities
-11 -5.37 -6.59 -8.96 -9.13 -12 -16 -21 -21 -21 -30
Net Income / (Loss) Continuing Operations
-13 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Consolidated Net Income / (Loss)
-16 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Depreciation Expense
0.27 0.30 0.13 0.04 0.05 0.05 0.02 0.01 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income
0.54 1.98 1.38 2.30 8.63 6.32 5.27 7.12 7.61 4.01 2.65
Changes in Operating Assets and Liabilities, net
0.63 -1.29 0.02 0.10 -0.57 -0.11 -1.16 -0.93 1.52 0.45 2.35
Net Cash From Investing Activities
-0.29 -0.01 0.00 -0.11 -0.01 -0.01 -0.01 -4.73 -0.01 -0.02 -0.02
Net Cash From Continuing Investing Activities
-0.13 -0.01 0.00 -0.11 -0.01 -0.01 -0.01 -4.73 -0.01 -0.02 -0.02
Purchase of Property, Plant & Equipment
-0.13 -0.01 0.00 -0.11 -0.01 -0.01 -0.01 -0.03 -0.01 -0.02 -0.02
Purchase of Investments
- - - - - - 0.00 -4.70 0.00 0.00 0.00
Net Cash From Financing Activities
9.46 4.70 11 12 11 39 113 0.00 -1.48 3.67 0.00
Net Cash From Continuing Financing Activities
9.46 4.70 11 12 11 39 113 0.00 -1.48 3.67 0.00
Other Financing Activities, net
- - 0.75 0.00 11 -0.01 44 - 0.00 3.67 0.00

Quarterly Cash Flow Statements for Atossa Genetics

This table details how cash moves in and out of Atossa Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-4.50 -4.43 -4.76 -3.68 -5.97 -7.26 -6.01 -11 -9.58 -5.62 -5.52
Net Cash From Operating Activities
-4.70 -4.53 -4.75 -7.05 -5.96 -7.26 -6.01 -11 -9.58 -9.64 -5.52
Net Cash From Continuing Operating Activities
-4.70 -4.53 -4.75 -7.05 -5.96 -7.26 -6.01 -11 -9.58 -9.64 -5.52
Net Income / (Loss) Continuing Operations
-5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59 -8.49 -5.64
Consolidated Net Income / (Loss)
-5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59 -8.49 -5.64
Depreciation Expense
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
0.42 0.35 2.46 0.78 0.56 0.80 0.78 0.50 0.72 0.82 0.55
Changes in Operating Assets and Liabilities, net
0.76 1.16 0.02 -1.49 0.19 0.36 1.90 -0.11 -0.72 -1.97 -0.43

Annual Balance Sheets for Atossa Genetics

This table presents Atossa Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
6.24 4.14 8.16 12 14 43 141 124 96 76 48
Total Current Assets
4.29 3.25 7.90 12 14 43 141 118 92 74 46
Cash & Equivalents
3.72 3.03 7.22 10 13 40 136 111 88 71 41
Restricted Cash
0.28 0.06 0.06 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Prepaid Expenses
0.19 0.17 0.25 0.51 0.86 1.81 2.49 6.45 3.65 3.26 4.21
Plant, Property, & Equipment, net
0.17 0.06 0.01 0.05 0.03 0.02 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
1.78 0.83 0.25 0.12 0.14 0.05 0.02 5.34 4.03 1.99 1.99
Long-Term Investments
- - - - - - 0.00 4.70 1.71 - 0.00
Other Noncurrent Operating Assets
0.08 0.19 0.18 0.02 0.07 0.04 - 0.64 2.32 1.99 1.99
Total Liabilities & Shareholders' Equity
6.24 4.14 8.16 12 14 43 141 124 96 76 48
Total Liabilities
2.50 1.05 1.23 2.92 1.33 16 3.13 5.57 5.24 4.97 8.26
Total Current Liabilities
2.50 1.05 1.23 2.92 1.32 16 3.13 5.57 5.24 4.97 8.26
Accounts Payable
0.81 0.25 0.33 0.35 0.29 1.59 1.72 2.97 0.81 0.68 4.29
Accrued Expenses
0.46 0.02 0.09 0.18 0.08 0.09 0.20 1.06 0.97 0.92 1.31
Current Employee Benefit Liabilities
1.16 0.77 0.78 2.35 0.90 0.96 1.18 1.53 1.65 1.86 1.56
Other Current Liabilities
0.06 0.01 0.02 0.04 0.05 13 0.02 0.02 1.80 1.51 1.10
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Total Preferred & Common Equity
3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Preferred Stock
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Common Stock
55 60 72 83 107 138 267 274 279 285 287
Retained Earnings
-51 -57 -65 -77 -94 -112 -129 -156 -186 -212 -247
Treasury Stock
- - - - - - - 0.00 -1.48 -1.48 -1.48

Quarterly Balance Sheets for Atossa Genetics

This table presents Atossa Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
102 91 86 79 71 65 58 38 32 26
Total Current Assets
98 87 82 77 69 63 56 37 31 25
Cash & Equivalents
94 84 80 75 65 58 52 32 26 21
Restricted Cash
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Prepaid Expenses
3.47 2.99 2.08 2.24 3.52 4.55 3.72 4.84 4.81 4.50
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
4.05 4.03 4.14 2.37 2.00 2.00 2.33 1.28 1.27 1.27
Long-Term Investments
1.71 1.71 1.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets
2.34 2.32 2.43 2.37 2.00 2.00 2.33 1.28 1.27 1.27
Total Liabilities & Shareholders' Equity
102 91 86 79 71 65 58 38 32 26
Total Liabilities
3.44 5.33 5.70 5.80 5.43 6.82 8.23 7.46 5.45 4.71
Total Current Liabilities
3.44 5.33 5.70 5.80 5.43 6.82 8.23 7.46 5.45 4.71
Accounts Payable
0.72 1.23 1.06 1.56 1.17 2.01 3.54 2.57 1.98 1.50
Accrued Expenses
1.26 1.61 1.91 1.69 1.79 2.20 1.99 2.81 1.38 1.30
Current Employee Benefit Liabilities
1.44 0.66 0.94 1.06 0.94 1.05 1.13 0.94 0.97 1.17
Other Current Liabilities
0.02 1.83 1.79 1.48 1.53 1.56 1.58 1.14 1.12 0.75
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
98 86 80 74 65 58 50 30 27 22
Total Preferred & Common Equity
98 86 80 74 65 58 50 30 27 22
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
98 86 80 74 65 58 50 30 27 22
Common Stock
278 279 280 281 285 286 287 288 293 293
Retained Earnings
-179 -192 -198 -205 -219 -227 -236 -256 -265 -270
Treasury Stock
-1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48

Annual Metrics And Ratios for Atossa Genetics

This table displays calculated financial ratios and metrics derived from Atossa Genetics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
30,446,260.00 7,575,934.00 26,522,741.00 5,646,552.00 9,130,984.00 10,492,835.00 126,624,110.00 126,624,110.00 125,304,064.00 - 129,171,424.00
DEI Adjusted Shares Outstanding
11,276.00 42,089.00 147,349.00 376,437.00 608,732.00 699,522.00 8,441,607.00 8,441,607.00 8,353,604.00 - 8,611,428.00
DEI Earnings Per Adjusted Shares Outstanding
-1,397.69 -151.32 -72.55 -60.79 -28.32 -31.92 -2.44 -3.19 -3.60 - -4.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-95.62% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-6.80% 51.42% -31.79% -42.12% -51.28% -3.46% -15.79% -35.16% -23.66% 19.14% -33.44%
EBIT Growth
-4.83% 50.08% -27.54% -40.41% -51.16% -3.41% -15.62% -35.05% -23.71% 19.15% -33.41%
NOPAT Growth
-4.83% 37.54% 4.01% -49.48% -51.00% 15.40% -40.49% -34.94% -13.31% 11.97% -34.47%
Net Income Growth
-7.52% 59.59% -27.54% -40.41% -51.16% -3.41% -15.58% -30.84% -11.62% 15.25% -36.33%
EPS Growth
-7.52% 74.01% -27.54% 49.86% 63.09% 2.96% 0.00% 0.00% -14.29% 16.67% -36.33%
Operating Cash Flow Growth
-32.19% 61.48% -22.69% -35.91% -1.86% -26.75% -42.37% -26.03% -0.87% -0.43% -41.52%
Free Cash Flow Firm Growth
-51.45% 28.58% 14.29% -32.87% -114.00% 119.22% -1,141.23% 29.72% -2.07% 7.61% -25.30%
Invested Capital Growth
-149.49% 105.68% -2,459.88% -404.97% 127.58% -2,788.07% 113.02% 39.15% -67.49% -61.55% -826.50%
Revenue Q/Q Growth
-35.20% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
6.45% 0.61% 5.68% -0.86% -3.26% -37.70% 11.36% -13.56% -12.43% 18.92% -12.73%
EBIT Q/Q Growth
6.29% 1.01% 6.13% -0.75% -3.23% -37.53% 11.37% -13.56% -12.47% 18.94% -12.73%
NOPAT Q/Q Growth
6.28% 1.39% 4.58% -1.01% -3.04% -12.37% -3.03% -13.60% -2.87% 6.33% -13.04%
Net Income Q/Q Growth
5.13% 27.68% 6.13% 0.00% 0.00% -37.53% 11.40% -10.94% -0.88% 5.23% -15.21%
EPS Q/Q Growth
5.13% 25.77% 6.13% 0.00% 0.00% -53.91% 0.00% 0.00% 0.00% 9.09% -15.21%
Operating Cash Flow Q/Q Growth
-9.70% 32.58% -5.21% -9.28% -2.99% -6.67% -1.43% -4.31% -5.27% -7.57% -13.28%
Free Cash Flow Firm Q/Q Growth
-25.17% 5.68% -13.42% -16.12% -3.29% 127.03% -96.69% 10.00% -17.63% -10.77% -7.42%
Invested Capital Q/Q Growth
-157.24% -98.54% -47.78% 30.39% 226.55% -2,003.88% 35.94% -64.51% -69.33% 123.68% 5.17%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
-7,431.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-710,213.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-725,746.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-725,721.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-896,491.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
123.53% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.97% 96.85% 87.39% 91.60% 93.60%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-7,024.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-6,918.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
6,785.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-238.07% -186.26% -161.87% -144.88% -157.00% -88.42% -24.93% -21.05% -28.80% -31.39% -62.74%
Cash Return on Invested Capital (CROIC)
0.00% -41,298.91% 0.00% 0.00% -3,062.40% 0.00% -1,750.93% -1,029.08% -1,362.39% -3,705.93% 0.00%
Operating Return on Assets (OROA)
-141.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-175.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-238.07% -186.26% -161.87% -144.88% -157.00% -88.42% -24.93% -21.05% -28.80% -31.39% -62.74%
Return on Equity Simple (ROE_SIMPLE)
-421.20% -205.64% -117.06% -129.53% -131.04% -65.62% -14.92% -22.85% -33.06% -35.68% 0.00%
Net Operating Profit after Tax (NOPAT)
-8.93 -5.58 -5.35 -8.00 -12 -10 -14 -19 -22 -19 -26
NOPAT Margin
-508,022.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-105.18% -22.36% -53.46% -38.29% -44.47% -29.04% -7.09% -6.01% -7.89% -7.64% -15.58%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -24.13% -27.05% -66.07%
Cost of Revenue to Revenue
7,531.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
584,093.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
134,220.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
718,314.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-13 -6.37 -8.12 -11 -17 -18 -21 -28 -34 -28 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-12 -6.07 -7.99 -11 -17 -18 -21 -28 -34 -28 -37
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.60 1.72 1.01 0.65 1.09 0.37 1.47 0.57 1.21 1.66 1.94
Price to Tangible Book Value (P/TBV)
4.77 2.17 1.02 0.66 1.10 0.37 1.47 0.57 1.21 1.66 1.94
Price to Revenue (P/Rev)
5,541.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 159.65 0.00 0.00 3.54 0.00 40.63 0.00 27.16 168.11 0.00
Enterprise Value to Revenue (EV/Rev)
3,271.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.98 -1.03 -1.03 -1.13 -1.06 -1.30 -1.07 -0.98 -0.99 -0.99 -1.02
Leverage Ratio
1.36 1.52 1.23 1.26 1.19 1.42 1.11 1.03 1.05 1.06 1.12
Compound Leverage Factor
1.36 1.52 1.23 1.26 1.19 1.42 1.11 1.00 0.92 0.97 1.05
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-15.48 -20.73 -10.11 -10.32 -5.49 -3.89 38.30 5.79 9.83 10.36 -3.34
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.72 3.11 6.45 3.96 10.83 2.73 45.18 21.23 17.61 14.99 5.53
Quick Ratio
1.49 2.89 5.89 3.56 9.51 2.52 43.63 19.92 16.89 14.31 5.00
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-8.18 -5.84 -5.01 -6.65 -14 2.74 -28 -20 -20 -19 -24
Operating Cash Flow to CapEx
-10,672.96% -58,337.01% 0.00% -8,080.38% -119,717.27% -128,555.56% -183,022.22% -76,888.89% -149,578.57% -110,684.21% -129,400.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,829.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
-1,829.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.25 0.01 -0.33 -1.69 0.46 -12 1.63 2.26 0.74 0.28 -2.06
Invested Capital Turnover
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.75 0.26 -0.35 -1.35 2.15 -13 14 0.64 -1.53 -0.45 -2.34
Enterprise Value (EV)
5.75 2.26 -0.30 -4.73 1.64 -30 66 -49 20 48 35
Market Capitalization
9.74 5.34 6.98 5.76 14 9.97 203 67 110 119 76
Book Value per Share
$0.12 $0.82 $0.26 $1.56 $1.44 $2.59 $1.09 $0.93 $0.73 $0.57 $0.30
Tangible Book Value per Share
$0.07 $0.65 $0.26 $1.54 $1.43 $2.59 $1.09 $0.93 $0.73 $0.57 $0.30
Total Capital
3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-3.99 -3.08 -7.27 -10 -13 -40 -136 -116 -90 -71 -41
Capital Expenditures (CapEx)
0.13 0.01 0.00 0.11 0.01 0.01 0.01 0.03 0.01 0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.20 -0.88 -0.60 -1.86 0.31 -13 1.63 1.63 -1.59 -1.70 -4.05
Debt-free Net Working Capital (DFNWC)
1.79 2.21 6.67 8.63 13 27 138 113 87 69 37
Net Working Capital (NWC)
1.79 2.21 6.67 8.63 13 27 138 113 87 69 37
Net Nonoperating Expense (NNE)
6.83 0.79 2.77 3.40 5.15 7.60 6.24 7.58 8.13 6.17 8.77
Net Nonoperating Obligations (NNO)
-3.99 -3.08 -7.27 -10 -13 -40 -137 -116 -90 -71 -41
Total Depreciation and Amortization (D&A)
0.27 0.30 0.13 0.04 0.05 0.05 0.02 0.01 0.02 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue
-125,007.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
102,005.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
102,005.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($99.00) ($33.60) ($10.92) ($5.50) ($2.03) ($1.97) ($0.18) ($0.21) ($0.24) ($0.20) ($4.04)
Adjusted Weighted Average Basic Shares Outstanding
215.69K 315.58K 2.65M 9.12M 9.13M 120.82M 126.62M 126.62M 126.08M 125.86M 8.61M
Adjusted Diluted Earnings per Share
($99.00) ($33.60) ($10.92) ($5.50) ($2.03) ($1.97) ($0.18) $0.00 ($0.24) ($0.20) ($4.04)
Adjusted Weighted Average Diluted Shares Outstanding
215.69K 315.58K 2.65M 9.12M 9.13M 120.82M 126.62M 126.62M 126.08M 125.86M 8.61M
Adjusted Basic & Diluted Earnings per Share
($99.00) ($33.60) ($10.92) ($5.50) ($2.03) ($1.97) ($0.18) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
157.93K 189.82K 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 125.30M 129.17M 8.61M
Normalized Net Operating Profit after Tax (NOPAT)
-8.93 -5.07 -5.03 -8.00 -12 -10 -14 -19 -22 -19 -26
Normalized NOPAT Margin
-508,022.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-725,721.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.90% 0.00% 0.00%

Quarterly Metrics And Ratios for Atossa Genetics

This table displays calculated financial ratios and metrics derived from Atossa Genetics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
125,304,064.00 125,757,416.00 125,757,416.00 - 129,170,004.00 129,170,004.00 129,171,424.00 129,171,424.00 8,611,361.00 8,611,361.00 9,979,298.00
DEI Adjusted Shares Outstanding
8,353,604.00 8,383,828.00 8,383,828.00 - 8,611,334.00 8,611,334.00 8,611,428.00 8,611,428.00 8,611,361.00 8,611,361.00 9,979,298.00
DEI Earnings Per Adjusted Shares Outstanding
-0.70 -0.72 -0.86 - -0.78 -0.98 -1.01 -1.27 -1.11 -0.99 -0.57
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
1.64% 8.98% 13.11% 54.28% -6.03% -27.34% -42.06% -58.40% -33.09% 3.86% 36.89%
EBIT Growth
1.61% 8.96% 13.09% 54.30% -6.01% -27.32% -42.03% -58.37% -33.07% 3.86% 36.87%
NOPAT Growth
1.66% 8.83% 14.50% 20.70% -6.22% -27.23% -44.89% -59.92% -33.13% 3.83% 36.23%
Net Income Growth
6.42% 38.46% -16.07% 18.15% -14.29% -39.25% -20.22% -72.32% -42.74% -0.81% 35.14%
EPS Growth
0.00% 37.50% -20.00% 33.33% -14.29% -40.00% -16.67% -72.32% -42.31% 3.06% 44.55%
Operating Cash Flow Growth
33.10% -1.48% -22.33% -26.57% -26.84% -60.21% -26.42% -49.47% -60.78% -32.86% 8.08%
Free Cash Flow Firm Growth
95.21% 97.29% 29.96% 4.85% -1,749.06% -5,810.20% -529.24% -24.46% -3.09% 3.54% -33.61%
Invested Capital Growth
-100.46% -132.29% -149.79% -61.55% 557.14% 77.03% -81.42% -826.50% -1,497.92% 330.15% 148.66%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
41.41% -1.53% 8.44% 33.50% -3.52% -21.93% -2.14% -22.87% 13.02% 11.93% 32.95%
EBIT Q/Q Growth
41.44% -1.51% 8.44% 33.48% -3.52% -21.91% -2.14% -22.86% 13.02% 11.92% 32.93%
NOPAT Q/Q Growth
22.60% -1.79% 10.13% -12.00% -3.68% -21.93% -2.33% -23.62% 13.69% 11.91% 32.15%
Net Income Q/Q Growth
24.19% -2.91% -19.52% 12.21% -5.85% -25.38% -3.19% -25.83% 12.33% 11.45% 33.60%
EPS Q/Q Growth
16.67% 0.00% -20.00% 33.33% -5.85% -40.00% 0.00% -25.83% 12.60% 14.41% 41.05%
Operating Cash Flow Q/Q Growth
15.67% 3.55% -4.83% -48.44% 15.49% -21.82% 17.28% -75.50% 9.09% -0.66% 42.76%
Free Cash Flow Firm Q/Q Growth
94.00% 57.32% -613.88% -420.61% -16.56% -36.43% 24.00% -2.97% 3.45% -27.65% -5.28%
Invested Capital Q/Q Growth
-102.85% -5,538.10% -0.93% 123.68% -66.08% -383.33% -697.06% 5.17% 34.73% 146.65% 68.53%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
83.78% 84.93% 110.87% 115.93% 90.32% 92.89% 93.85% 96.12% 96.88% 97.40% 96.43%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-29.84% -28.00% -31.30% -31.39% -34.87% -41.66% -48.89% -62.74% -78.58% -89.23% -96.90%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -3,705.93% -20,578.65% 0.00% 0.00% 0.00% 0.00% -4,532.54% -2,687.42%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-29.84% -28.00% -31.30% -31.39% -34.87% -41.66% -48.89% -62.74% -78.58% -89.23% -96.90%
Return on Equity Simple (ROE_SIMPLE)
-34.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.89 -4.97 -4.47 -5.01 -5.19 -6.33 -6.48 -8.01 -6.91 -6.09 -4.13
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-1.02% -1.18% -3.23% -1.66% -2.02% -3.01% -3.49% -5.21% -5.52% -5.72% -4.15%
Return On Investment Capital (ROIC_SIMPLE)
-5.70% -6.20% -6.07% -7.00% -7.94% -10.97% -13.01% -20.34% -22.66% -22.68% -18.99%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-7.02 -7.12 -6.52 -5.48 -7.44 -9.07 -9.26 -11 -9.90 -8.72 -5.85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.01 -7.12 -6.52 -5.47 -7.43 -9.06 -9.26 -11 -9.89 -8.71 -5.84
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.63 1.87 2.59 1.66 1.33 1.86 2.25 1.94 1.49 0.62 0.90
Price to Tangible Book Value (P/TBV)
2.63 1.87 2.59 1.66 1.33 1.86 2.25 1.94 1.49 0.62 0.90
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 168.11 225.96 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.98 -0.99 -0.99 -0.99 -1.00 -1.01 -1.03 -1.02 -1.01 -1.00 -1.02
Leverage Ratio
1.04 1.05 1.05 1.06 1.07 1.09 1.11 1.12 1.13 1.15 1.18
Compound Leverage Factor
0.87 0.89 1.17 1.23 0.97 1.01 1.05 1.08 1.10 1.12 1.14
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
23.27 13.32 16.98 11.32 6.02 5.08 2.94 -1.56 -5.74 -9.59 -11.63
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
16.34 14.35 13.30 14.99 12.67 9.17 6.77 5.53 4.92 5.69 5.35
Quick Ratio
15.76 13.96 12.90 14.31 12.00 8.48 6.30 5.00 4.25 4.79 4.37
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-0.29 -0.12 -0.87 -4.55 -5.31 -7.24 -5.50 -5.67 -5.47 -6.98 -7.35
Operating Cash Flow to CapEx
-78,300.00% -151,033.33% -47,500.00% 0.00% -66,211.11% 0.00% -85,785.71% -150,557.14% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.02 -1.18 -1.20 0.28 0.10 -0.27 -2.17 -2.06 -1.34 0.63 1.06
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-4.60 -4.85 -3.60 -0.45 0.12 0.91 -0.97 -2.34 -1.44 0.90 3.22
Enterprise Value (EV)
140 68 116 48 22 49 60 35 13 -9.58 -1.22
Market Capitalization
226 150 191 119 87 107 112 76 45 17 19
Book Value per Share
$0.68 $0.64 $0.59 $0.57 $0.51 $0.45 $0.39 $0.30 $3.54 $3.12 $2.18
Tangible Book Value per Share
$0.68 $0.64 $0.59 $0.57 $0.51 $0.45 $0.39 $0.30 $3.54 $3.12 $2.18
Total Capital
86 80 74 71 65 58 50 39 30 27 22
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-86 -81 -75 -71 -65 -58 -52 -41 -32 -26 -21
Capital Expenditures (CapEx)
0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.34 -3.61 -3.56 -1.70 -1.91 -2.27 -4.50 -4.05 -2.62 -0.65 -0.21
Debt-free Net Working Capital (DFNWC)
82 76 71 69 63 56 47 37 29 26 20
Net Working Capital (NWC)
82 76 71 69 63 56 47 37 29 26 20
Net Nonoperating Expense (NNE)
0.99 1.08 2.76 1.34 1.53 2.10 2.22 2.93 2.68 2.41 1.51
Net Nonoperating Obligations (NNO)
-86 -81 -75 -71 -65 -58 -52 -41 -32 -26 -21
Total Depreciation and Amortization (D&A)
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.05) ($0.05) ($0.06) ($0.04) ($0.75) ($0.07) ($0.07) ($19.05) ($1.11) ($0.95) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding
125.32M 125.73M 125.77M 125.86M 8.61M 129.17M 129.17M 574.09K 8.62M 8.91M 9.99M
Adjusted Diluted Earnings per Share
($0.05) ($0.05) ($0.06) ($0.04) ($0.75) ($0.07) ($0.07) ($19.05) ($1.11) ($0.95) ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding
125.32M 125.73M 125.77M 125.86M 8.61M 129.17M 129.17M 574.09K 8.62M 8.91M 9.99M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($19.05) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
125.76M 125.76M 125.80M 129.17M 8.61M 129.17M 129.17M 574.09K 8.61M 9.98M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-4.89 -4.97 -4.47 -5.01 -5.19 -6.33 -6.48 -8.01 -6.91 -6.09 -4.13
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-4.97% -5.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Atossa Genetics remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial statements show persistent operating losses, significant research spending and a steadily declining cash balance. The most recent quarter included some improvement in expenses and a financing inflow, but the company continues to consume cash and has not yet reached commercial revenue generation.

  • Strong balance-sheet liquidity relative to liabilities: At June 30, 2026, Atossa reported $26.1 million in cash and equivalents, $31.0 million in current assets and only $5.5 million in current liabilities. The company also reported no noncurrent liabilities, giving it a current ratio of approximately 5.7.
  • Quarterly operating expenses improved: Total operating expenses declined to $8.7 million in Q2 2026 from $9.9 million in Q1 2026 and $11.4 million in Q4 2025. Selling, general and administrative expense fell to $3.8 million, while research and development expense was relatively stable at $4.9 million.
  • Financing activity partially supported liquidity: Atossa generated $4.0 million of financing cash flow in Q2 2026. This helped offset part of the $9.6 million operating cash burn, although the quarter still ended with a $5.6 million decline in cash.
  • Investment income provides a modest offset: Interest and investment income contributed $227,000 in Q2 2026 and has helped reduce, but not eliminate, operating losses in recent periods.
  • Research spending remains a major priority: Research and development expense was $4.9 million in Q2 2026, representing more than half of total operating expenses. This spending may support future clinical and commercial opportunities, but the financial statements do not yet show revenue or a return on that investment.
  • Share-count data requires caution: Reported weighted-average shares changed substantially between periods, including a decline from more than 129 million in parts of 2025 to 8.9 million in Q2 2026. This may reflect a reverse split, restatements or other capital-structure changes, making direct per-share comparisons difficult without reviewing the company’s filings.
  • No revenue has been reported: Total revenue was listed as zero in every income statement provided from Q3 2023 through Q2 2026. Atossa therefore remains dependent on cash reserves and external financing rather than operating revenue.
  • Losses remain persistent: Atossa reported a net loss of $8.5 million in Q2 2026, following losses of $9.6 million in Q1 2026, $10.9 million in Q4 2025 and $8.7 million in Q3 2025. The company has not produced a profitable quarter in the supplied data.
  • Operating cash burn continues: Cash flow from operations was negative in every period provided. The Q2 2026 operating cash outflow of $9.6 million was roughly consistent with the $9.6 million net loss, indicating that losses are translating directly into cash consumption.
  • Cash reserves have declined sharply: Cash and equivalents fell from $94.0 million at September 30, 2023, to $26.1 million at June 30, 2026. Total assets declined from $101.7 million to $32.3 million over the same comparison, highlighting the effect of sustained losses and cash usage.
  • Accumulated losses have weakened equity: Retained earnings were negative $264.6 million at June 30, 2026, compared with negative $178.5 million at September 30, 2023. Total common equity fell to $26.8 million from $98.3 million over that period.
  • External capital may remain necessary: Although Atossa has no long-term debt and maintains more current assets than current liabilities, its recent operating burn suggests that additional financing could be needed if revenue generation or spending reductions do not occur. Future financing could create dilution or otherwise pressure existing shareholders.

Overall, Atossa’s balance sheet remains relatively lightly leveraged, but its investment case is primarily dependent on clinical and commercial progress rather than current financial performance. The key trends for investors are the absence of revenue, recurring multimillion-dollar losses, ongoing cash depletion and the company’s ability to secure capital while advancing its pipeline.

11/22/26 12:35 PM ETAI Generated. May Contain Errors.

Atossa Genetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Atossa Genetics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Atossa Genetics' net income appears to be on a downward trend, with a most recent value of -$34.77 million in 2025, falling from -$15.76 million in 2015. The previous period was -$25.50 million in 2024. See where experts think Atossa Genetics is headed by visiting Atossa Genetics' forecast page.

Atossa Genetics' total operating income in 2025 was -$37.14 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $37.14 million

Over the last 10 years, Atossa Genetics' total revenue changed from $1.76 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Atossa Genetics' cash and equivalents has ranged from $20.57 million in Q3 2026 to $94.03 million in Q3 2023, and is currently $20.57 million as of their latest financial filing in Q3 2026.

Atossa Genetics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Atossa Genetics' book value per share changed from 0.12 in 2015 to 0.30 in 2025, a change of 147.9%.



Financial statements for NASDAQ:ATOS last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners